Bad Vilbel/Belgrade, September 9, 2013 – In future, the STADA Group will bring together a significant portion of its IT services in its own shared service center and, through the elimination of external consulting, will save a substantial share of the previous costs. STADA IT SOLUTIONS DOO will be established specifically for this purpose. The company, which will only provide intercompany services, will be part of Hemofarm A.D. a wholly-owned subsidiary of the STADA Group in Serbia. Approximately 85 employees at the Serbian Hemofarm locations in Vrsac and Belgrade will be focused primarily on the implementation of SAP and Microsoft projects and the corresponding support for the entire Group. These projects include SAP roll-outs, upgrades and the introduction of new Sharepoint solutions.

"With STADA IT SOLUTIONS we have found a way to save millions every year whilst at the same time not just safeguarding jobs but also creating new ones", explains Angela Weißenberger, CIO of the STADA Group. "The great expertise and experience of our Serbian IT colleagues from Hemofarm puts us in a position to have the implementation and support of SAP and Microsoft projects in the Group performed by our own employees in future and to dispense with the use of costly external consultants. Thus from 2014 we will realize net cost savings of over two million euros in the IT budget, based on the present workload and cost volumes. From 2015 we even calculate that we will make annual savings of significantly more than three million euros."
In future the approximately 60 employees of what is currently Hemofarm IT will be part of the newly established STADA IT SOLUTIONS. As the new shared service center will take over projects for the entire STADA Group, the capacity will be increased, creating approximately 25 additional jobs.
"The consistent utilization of the cost advantages offered by the Serbian location which at the same time offers a very high level of quality allows the entire Group to benefit from STADA IT SOLUTIONS", says Weißenberger. "This is a good example of the positive effects, also in terms of costs, arising from STADA consistently pursuing its internationalization strategy.

About STADA Arzneimittel AG and Hemofarm A.D.:
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group traditionally has a strong presence in Europe and is the only independent generics producer in Germany. Worldwide, STADA is one of the five leading companies in the generics industry and is represented in more than 30 countries with approximately 50 subsidiaries. Branded products such as Mobilat, Grippostad and Ladival are among the highest selling in their product category in Germany. In financial year 2012, STADA achieved Group sales of Euro 1.837,5 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 367.5 million and adjusted net income of Euro 147.9 million. As of December 31, 2012, STADA employed 7,761 people worldwide. Since 2006 Hemofarm A.D. is a wholly-owned subsidiary of the STADA Group. It is the leading generic pharmaceutical company in Serbia and region and the biggest exporter of drugs from the country, Hemofarm is present in more than 30 countries with its wide offer of efficient, high-quality products.
For more information, please contact:

STADA Arzneimittel AG
Media Relations
61118 Bad Vilbel
Tel.: +49 6101 603-165
Fax: +49 6101 603-506
e-mail: press@stada.de